SZodixStudyAcademic Library

Shelves Open access

Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated

William Kenneth Evans · Study

Home/Author

William Kenneth Evans

16 works· latest 2019· 7 institutionscluster: provisionalORCID 0000-0003-2069-1593

h-index16

i1016

Citations1,056

Works here16

95

96

97

98

99

00

01

03

07

09

10

14

19

Most cited in this library

Estimates of the lifetime costs of breast cancer treatment in Canada2000 · 147 citations
Economic guidelines for oncology products: Adaptation of the Canadian Agency for Drugs and Technologies in Health (CADTH) technology assessment guidance document2009 · 80 citations
Economic Analysis: Randomized Placebo-Controlled Clinical Trial of Erlotinib in Advanced Non-Small Cell Lung Cancer2010 · 76 citations
Continental Divide? The Attitudes of US and Canadian Oncologists on the Costs, Cost-Effectiveness, and Health Policies Associated With New Cancer Drugs2010 · 76 citations
Decision Framework for Chemotherapeutic Interventions for Metastatic Non-Small-Cell Lung Cancer2000 · 71 citations

Works

16 shown

Cost-of-Illness Study for Non-Small-Cell Lung Cancer Using Real-World Data

Current Oncology·2019·5 authors·Open access

48citations

Health System Costs for Stage-Specific Breast Cancer: A Population-Based Approach

Current Oncology·2014·13 authors·Open access

68citations

Continental Divide? The Attitudes of US and Canadian Oncologists on the Costs, Cost-Effectiveness, and Health Policies Associated With New Cancer Drugs

Journal of Clinical Oncology·2010·7 authors·Open access

76citations

Economic Analysis: Randomized Placebo-Controlled Clinical Trial of Erlotinib in Advanced Non-Small Cell Lung Cancer

JNCI Journal of the National Cancer Institute·2010·10 authors

76citations

Economic guidelines for oncology products: Adaptation of the Canadian Agency for Drugs and Technologies in Health (CADTH) technology assessment guidance document

Journal of Clinical Oncology·2009·8 authors·other

80citations

Health technology assessment: A comprehensive framework for evidence-based recommendations in Ontario

International Journal of Technology Assessment in Health Care·2009·10 authors

70citations

Economic Analysis of NCIC CTG JBR.10: A Randomized Trial of Adjuvant Vinorelbine Plus Cisplatin Compared With Observation in Early Stage Non–Small-Cell Lung Cancer—A Report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group

Journal of Clinical Oncology·2007·15 authors·Open access

50citations

Lifetime costs of colon and rectal cancer management in Canada.

PubMed·2003·6 authors

53citations

Canada's Population Health Model (POHEM)

European Journal of Cancer·2001·3 authors

54citations

Decision Framework for Chemotherapeutic Interventions for Metastatic Non-Small-Cell Lung Cancer

JNCI Journal of the National Cancer Institute·2000·6 authors

71citations

Estimates of the lifetime costs of breast cancer treatment in Canada

European Journal of Cancer·2000·5 authors

147citations

Cost-effectiveness of paclitaxel plus cisplatin in advanced non-small-cell lung cancer

British Journal of Cancer·1999·2 authors·Open access

48citations

Cost-effectiveness analysis in oncology

Annals of Oncology·1998·3 authors·Open access

51citations

Cost of combined modality interventions for stage III non-small-cell lung cancer.

Journal of Clinical Oncology·1997·4 authors

52citations

The economics of lung cancer management in Canada

Lung Cancer·1996·4 authors

52citations

Estimating the cost of lung cancer diagnosis and treatment in Canada: the POHEM model.

PubMed·1995·4 authors

60citations